Click here to join

Investors & Media

What's new.

Press releases

Press releases.

Immutep Presents New and Significant Data from the AIPAC Study

May 4th 2022
press releases

Immutep Quarterly Activities Report

April 29th 2022
press releases

Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting

April 28th 2022
press releases

Investor updates

Investor updates.

Investor Update - February 2022

February 18th 2022
investor updates

Investor Update - April 2021

April 14th 2021
investor updates

Investor Update - August 2020

August 17th 2020
investor updates

Analyst reports

Analyst reports.

Maxim Group - Disappointing Data for TIGIT; Nice Set up for Immutep’s soluble LAG-3 in 1L NSCLC? ASCO is Next (Analyst: Dr Naureen Quibria)

For a copy of this analyst report please contact your Maxim advisor John Law - jlaw@maximgrp.com or biotech analyst Naureen Quibria - nquibria@maximgrp.com

May 12th 2022
analyst reports

CLSA Equity Research - Raising the profile - AIPAC data continues to support MOA ahead of key conference (ASX:IMM) (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor.

May 5th 2022
analyst reports

Bell Potter - Breast cancer trial data supports mechanism of action (Analyst: Dr Tara Speranza)

May 5th 2022
analyst reports